

Lee N Lawton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1353016/publications.pdf>

Version: 2024-02-01

8
papers

284
citations

1937685
4
h-index

2272923
4
g-index

8
all docs

8
docs citations

8
times ranked

659
citing authors

#	ARTICLE	IF	CITATIONS
1	MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8. <i>Blood</i> , 2021, 138, 1324-1324.	1.4	0
2	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 713-713.	1.4	0
3	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.	30.7	87
4	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , 2020, 105, 1361-1368.	3.5	23
5	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. <i>Blood Advances</i> , 2019, 3, 4065-4080.	5.2	99
6	Targeted inhibition of PI3K $\hat{\pm}$ / $\hat{\nu}$ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. <i>Blood</i> , 2019, 133, 70-80.	1.4	75
7	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. <i>Blood</i> , 2019, 134, 1493-1493.	1.4	0
8	Targeted Inhibition of PI3K $\hat{\pm}$ / $\hat{\nu}$ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL. <i>Blood</i> , 2018, 132, 39-39.	1.4	0